C4 Therapeutics (CCCC) announced the continued evolution of its Board of Directors with the appointment of Steve Hoerter as a director.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CCCC:
- C4 Therapeutics initiated with an Equal Weight at Stephens
- C4 Therapeutics announces first patient dosed in CFT8919 clinical trial
- C4 Therapeutics Advances in Protein Degradation Therapy
- C4 Therapeutics files $400M mixed securities shelf
- C4 Therapeutics files to sell 4.87M shares of common stock for holders